-

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp

BARCELONA, Spain--(BUSINESS WIRE)--Spanish pharmaceutical company Ferrer has reaffirmed its status as a B Corp, an international certification awarded to companies that operate with a business model centered on positive impact and meet high social, environmental, and community standards. Ferrer has achieved a score of 136.4 points, making it the highest-rated pharmaceutical company in the world. Additionally, it now ranks as the third-highest scoring company across all sectors globally among those generating more than €500 million in annual revenue.

According to Mario Rovirosa, CEO of Ferrer, “This achievement reflects our firm commitment to using business to fight for social justice. Every member of our organization works daily to ensure that we are not just one of the best companies in the world, but one of the best companies for the world. However, while we are immensely proud of this recognition, we believe it is not enough. We have a moral obligation to do more and do better because the global reality of social injustice is urgent. Only by all working together can we really tackle today’s and tomorrow’s challenges.”

To become a B Corp, companies must undergo a rigorous assessment and achieve a minimum score of 80 points across five key areas: governance, customers, environment, employees, and community. In 2022, Ferrer obtained a score of 100.6, becoming the first Spanish pharmaceutical company to join the B Corp movement. Now, three years later, it has improved its score by 35%.

Over the intervening period, Ferrer has implemented more than 100 initiatives that have contributed to raising its score across all five impact areas. The most significant increase occurred in the Community category, where the company’s score rose from 13.2 to 38 points. This improvement was primarily driven by the recognition of Ferrer’s Impact Business Model (IBM) for Donations, as well as enhancements in social and environmental supply chain management.

The Impact Business Model for Donations formalizes Ferrer’s commitment to donating at least 20% of its total annual profits, with a minimum of 10% allocated to the Ferrer Foundations and the remainder directed towards other social and environmental organizations. In fact, over the past four years, Ferrer has exceeded this commitment, dedicating an average of 40% of its profits to initiatives that generate a positive impact.

This model complements Ferrer’s established Health Impact Business Model, which was recognized in the initial certification. As a pharmaceutical company, Ferrer is dedicated to providing transformative therapeutic solutions for those with debilitating, low-prevalence diseases, particularly in the fields of pulmonary vascular and interstitial lung diseases and neurological disorders.

Mario Rovirosa also stated that, “At Ferrer, we firmly believe that business success must go hand in hand with generating a positive impact, both for society and the planet. As such, we have long been undergoing a transformation that extends beyond traditional business activities, positioning Ferrer as a company committed to action to drive social change. This approach has not only strengthened our identity and purpose but has also proven that sustainability and profitability can coexist without compromise. Our business model demonstrates that economic value creation can go hand in hand with actively contributing to a fairer and more sustainable world.”

Contacts

For more information:

Ferrer
Gorka Ortiz de Zárate
Communication Advisor
gortizdez@ferrer.com
Tel. +34 936 003 779

Ferrer

Details
Headquarters: Barcelona, Spain
CEO: Mario Rovirosa
Employees: 1.800
Organization: PRI


Contacts

For more information:

Ferrer
Gorka Ortiz de Zárate
Communication Advisor
gortizdez@ferrer.com
Tel. +34 936 003 779

More News From Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patie...

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer has achieved Compliance Leader Verification™, the prestigious recognition granted by Ethisphere, which distinguishes the pharmaceutical company as a global leader in upholding ethical and responsible corporate practices in its business operations. Ethisphere is a leading organization dedicated to advancing ethical business practices, and its recognition acknowledges organizations with an outstanding commitment to robust ethics and compliance programs. T...

The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

MADRID--(BUSINESS WIRE)--The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines1. This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This...
Back to Newsroom